Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

Choy, Ernest; Groves, Lara; Sugrue, Daniel; Hurst, Michael; Houghton, John; Venkatachalam, Srinivasan; Patel, Yusuf I.; Maxwell, James R.; Pollock, Kevin G.; Henning, Sadie

doi:10.1186/s41927-020-00173-0

BMC Rheumatology

Table 6 Incremental change in DAS28-ESR and DAS28-CRP at 12 months after LOT initiation

From: Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

Antibody Status	From 12 months
	Abatacept			Other bDMARD			Incremental difference
	Cohort (n)	Mean	95% CI	Cohort (n)	Mean	95% CI	LS Mean	95% CI	P value
DAS28-ESR
All patients	61	−1.98	−2.41,-1.55	113	−1.42	− 1.76,-1.08	− 0.56	− 1.04,-0.07	0.03
ACPA+	33	−1.84	−2.44,-1.23	46	−1.51	−2.05,-0.97	− 0.33	− 1.04,0.38	0.37
ACPA-	11	−2.44	− 3.53,-1.35	24	−1.79	−2.71,-0.88	−0.64	− 1.70,0.41	0.23
RF+	42	−1.99	−2.51,-1.46	74	−1.43	−1.85,-1.01	−0.56	− 1.16,0.05	0.07
RF-	14	−1.90	−2.88,-0.92	28	−1.77	−2.62,-0.93	−0.12	− 1.04,0.79	0.80
ACPA+/RF+	31	−1.83	−2.46,-1.21	42	−1.46	−2.02,-0.90	−0.37	−1.12,0.38	0.33
ACPA+/RF-	^a	−2.75	−28.19,22.70	^a	−1.46	−59.19,56.28	−1.29	−6.91,4.33	0.67
ACPA−/RF+	^a	−2.21	−4.91,0.49	6	−0.91	−2.87,1.06	−1.30	−3.75,1.14	0.32
ACPA−/RF-	9	−2.30	−3.41,-1.18	18	−1.89	−2.84,-0.94	−0.41	− 1.55,0.74	0.49
DAS28-CRP
All patients	91	−1.86	−2.16,-1.56	90	−1.50	− 1.80,-1.19	−0.37	− 0.75,0.01	0.06
ACPA+	35	−1.79	−2.30,-1.28	33	−1.52	−2.07,-0.98	−0.26	−0.88,0.35	0.40
ACPA-	9	− 1.85	−2.88,-0.83	16	−1.28	−2.10,-0.45	−0.58	− 1.79,0.64	0.36
RF+	65	−2.02	− 2.38,-1.67	57	−1.53	−1.92,-1.14	−0.49	−0.95,-0.03	0.04
RF-	14	−1.58	−2.44,-0.72	21	−1.66	−2.42,−0.90	0.08	-0.90,1.07	0.87
ACPA+/RF+	33	−1.79	−2.29,-1.28	31	−1.39	− 1.93,-0.84	− 0.40	− 1.03,0.24	0.22
ACPA+/RF-	^a	−2.71	−13.76,8.35	^a	−2.73	−15.73,10.28	0.02	−3.62,3.66	0.99
ACPA−/RF+	^a	−2.28	− 3.49,-1.08	^a	−1.26	−2.77,0.26	−1.03	− 2.60,0.55	0.23
ACPA−/RF-	^a	−1.23	−2.71,0.25	12	−1.15	−2.05,-0.24	−0.08	−1.74,1.57	0.92

bDMARD Biologic disease-modifying antirheumatic drugs, CI Confidence interval, CRP c-reactive protein, DAS Disease activity score, ESR Erythrocyte sedimentation rate, n Is the number of patients with a DAS score recorded at LOT initiation and at 12 months
^aCells suppressed due to small numbers

Back to article page

ISSN: 2520-1026

Contact us

Submission enquiries: bmcrheumatology@biomedcentral.com
General enquiries: ORSupport@springernature.com